Everest Medicines Balance Sheet Health
Financial Health criteria checks 5/6
Everest Medicines has a total shareholder equity of CN¥4.1B and total debt of CN¥526.1M, which brings its debt-to-equity ratio to 12.9%. Its total assets and total liabilities are CN¥5.0B and CN¥886.1M respectively.
Key information
12.92%
Debt to equity ratio
CN¥526.06m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.60b |
| Equity | CN¥4.07b |
| Total liabilities | CN¥886.05m |
| Total assets | CN¥4.96b |
Recent financial health updates
Everest Medicines (HKG:1952) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 01
Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?
Apr 27Recent updates
Everest Medicines Limited's (HKG:1952) Shares Climb 26% But Its Business Is Yet to Catch Up
Jun 12Everest Medicines (HKG:1952) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 01The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%
Apr 08
NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks
Dependence on NEFECON's success and market strategies in the IgAN space may not deliver the expected revenue, posing financial risks.Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?
Apr 27Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 31A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)
Jan 31Financial Position Analysis
Short Term Liabilities: 1952's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥793.5M).
Long Term Liabilities: 1952's short term assets (CN¥2.0B) exceed its long term liabilities (CN¥92.5M).
Debt to Equity History and Analysis
Debt Level: 1952 has more cash than its total debt.
Reducing Debt: 1952 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1952 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1952 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/10 05:50 |
| End of Day Share Price | 2025/08/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Everest Medicines Limited is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |